Shares of Stoke Therapeutics sank Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.0, a high estimate of $47.00 ...

Ed Kaye, former CEO of Sarepta Therapeutics, is stepping down from his current role as chief executive of a Boston-area ...

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...

Stoke Therapeutics' chief executive, Edward Kaye, is stepping down after more than seven years at the helm of the biotechnology company. Stoke on Tuesday said Ian Smith, a board member since September ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 64.71% and 483.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

George Weaver joins BBC Radio Stoke's Lucas Yeomans to discuss the Potters' last-gasp defeat by Millwall at The Den.

The response has been so strong that Ms Poole and Ms Wood are now on the lookout for a bigger premises – and have applied to ...

BEDFORD, Mass. - Stoke Therapeutics, Inc. (NASDAQ: STOK) shares dropped 4.1% after the biotechnology company announced its CEO Edward M. Kaye will step down, overshadowing better-than-expected fourth ...

Plans have been approved to knock down a "rundown" former Stoke-on-Trent school and youth centre plagued by "ongoing ...

Organised crime cops have seized a gun and bullets after morning raids at two Stoke-on-Trent homes. Three knuckle dusters and ...